{"id":16,"date":"2026-02-20T18:49:41","date_gmt":"2026-02-20T17:49:41","guid":{"rendered":"https:\/\/5-ht7r.org\/?page_id=16"},"modified":"2026-02-20T20:21:00","modified_gmt":"2026-02-20T19:21:00","slug":"bibliographie","status":"publish","type":"page","link":"https:\/\/5-ht7r.org\/?page_id=16","title":{"rendered":"Bibliographie"},"content":{"rendered":"\n

1. Walther D J<\/strong>, et al.<\/em><\/strong>, Synthesis of serotonin by a second tryptophan hydroxylase isoform<\/strong>. <\/em><\/strong>Science, 2003. 299(5603), 76, <\/strong>{Link} <\/strong><\/p>\n\n\n\n

2. Bard J A, et al.<\/em>, Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. <\/em>J Biol Chem, 1993<\/strong>. 268(31), 23422-23426, {Link} <\/p>\n\n\n\n

3. Lovenberg T W, et al.<\/em>, A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. <\/em>Neuron, 1993<\/strong>. 11(3), 449-458, {Link} <\/p>\n\n\n\n

4. Ruat M, et al.<\/em>, Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. <\/em>Proc Natl Acad Sci U S A, 1993<\/strong>. 90(18), 8547-8551, {Link} <\/p>\n\n\n\n

5. Hedlund P B and J G Sutcliffe, Functional, molecular and pharmacological advances in 5-HT7 receptor research. <\/em>Trends Pharmacol Sci, 2004<\/strong>. 25(9), 481-486, {Link} <\/p>\n\n\n\n

6. Yaakob N S, et al.<\/em>, Distribution of 5-HT3, 5-HT4, and 5-HT7 Receptors Along the Human Colon. <\/em>J Neurogastroenterol Motil, 2015<\/strong>. 21(3), 361-369, {Link} <\/p>\n\n\n\n

7. Quintero-Villegas A and S I Valdes-Ferrer, Role of 5-HT7 receptors in the immune system in health and disease. <\/em>Mol Med, 2019<\/strong>. 26(1), 2, {Link} <\/p>\n\n\n\n

8. Brenchat A, et al.<\/em>, Pharmacological activation of 5-HT7 receptors reduces nerve injury-induced mechanical and thermal hypersensitivity. <\/em>Pain, 2010<\/strong>. 149(3), 483-494, {Link} <\/p>\n\n\n\n

9. Nikiforuk A, Targeting the Serotonin 5-HT7 Receptor in the Search for Treatments for CNS Disorders: Rationale and Progress to Date. <\/em>CNS Drugs, 2015<\/strong>. 29(4), 265-275, {Link} <\/p>\n\n\n\n

10. Zareifopoulos N and C Papatheodoropoulos, Effects of 5-HT-7 receptor ligands on memory and cognition. <\/em>Neurobiol Learn Mem, 2016<\/strong>. 136, 204-209, {Link} <\/p>\n\n\n\n

11. Heidmann D E, et al.<\/em>, Four 5-hydroxytryptamine7 (5-HT7) receptor isoforms in human and rat produced by alternative splicing: species differences due to altered intron-exon organization. <\/em>J Neurochem, 1997<\/strong>. 68(4), 1372-1381, {Link} <\/p>\n\n\n\n

12. Krobert K A, et al.<\/em>, The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution. <\/em>Naunyn Schmiedebergs Arch Pharmacol, 2001<\/strong>. 363(6), 620-632, {Link} <\/p>\n\n\n\n

13. Guthrie C R, et al.<\/em>, Differential agonist-mediated internalization of the human 5-hydroxytryptamine 7 receptor isoforms. <\/em>J Pharmacol Exp Ther, 2005<\/strong>. 313(3), 1003-1010, {Link} <\/p>\n\n\n\n

14. Blattner K M, et al.<\/em>, Pharmacology and Therapeutic Potential of the 5-HT7 Receptor. <\/em>ACS Chem Neurosci, 2019<\/strong>. 10(1), 89-119, {Link} <\/p>\n\n\n\n

15. Deau E<\/strong>, et al.<\/em><\/strong>, Rational Design, Pharmacomodulation, and Synthesis of Dual 5-Hydroxytryptamine 7 (5-HT7)\/5-Hydroxytryptamine 2A (5-HT2A) Receptor Antagonists and Evaluation by [(18)F]-PET Imaging in a Primate Brain<\/strong>. <\/em><\/strong>J Med Chem, 2015. 58(20), 8066-8096, <\/strong>{Link} <\/strong><\/p>\n\n\n\n

16. Lundstrom K, Latest development in drug discovery on G protein-coupled receptors. <\/em>Curr Protein Pept Sci, 2006<\/strong>. 7(5), 465-470, {Link} <\/p>\n\n\n\n

17. Pierce K L, et al.<\/em>, Seven-transmembrane receptors. <\/em>Nat Rev Mol Cell Biol, 2002<\/strong>. 3(9), 639-650, {Link} <\/p>\n\n\n\n

18. El Khamlichi C<\/strong>, et al.<\/em><\/strong>, Serodolin, a beta-arrestin-biased ligand of 5-HT7 receptor, attenuates pain-related behaviors<\/strong>. <\/em><\/strong>Proc Natl Acad Sci U S A, 2022. 119(21), e2118847119, <\/strong>{Link} <\/strong><\/p>\n\n\n\n

19. Hogendorf A S, et al.<\/em>, Fluorinated indole-imidazole conjugates: Selective orally bioavailable 5-HT(7) receptor low-basicity agonists, potential neuropathic painkillers. <\/em>Eur J Med Chem, 2019<\/strong>. 170, 261-275, {Link} <\/p>\n\n\n\n

20. MacKinnon A C, et al.<\/em>, Bombesin and substance P analogues differentially regulate G-protein coupling to the bombesin receptor. Direct evidence for biased agonism. <\/em>J Biol Chem, 2001<\/strong>. 276(30), 28083-28091, {Link} <\/p>\n\n\n\n

21. Kolb P, et al.<\/em>, Community guidelines for GPCR<\/span> ligand bias: IUPHAR<\/span> review 32. <\/em>Br J Pharmacol, 2022<\/strong>. 179(14), 3651-3674, {Link} <\/p>\n\n\n\n

22. Kenakin T, Functional selectivity through protean and biased agonism: who steers the ship? Mol Pharmacol, 2007<\/strong>. 72(6), 1393-1401, {Link} <\/p>\n\n\n\n

23. Wisler J W, et al.<\/em>, Biased G Protein-Coupled Receptor Signaling: Changing the Paradigm of Drug Discovery. <\/em>Circulation, 2018<\/strong>. 137(22), 2315-2317, {Link} <\/p>\n\n\n\n

24. Lane J R, et al.<\/em>, A kinetic view of GPCR<\/span> allostery and biased agonism. <\/em>Nat Chem Biol, 2017<\/strong>. 13(9), 929-937, {Link} <\/p>\n\n\n\n

25. Watts S W, et al.<\/em>, beta-arrestin biased signaling is not involved in the hypotensive actions of 5-HT(7) receptor stimulation: use of Serodolin. <\/em>Pharmacol Res, 2024<\/strong>. 199, 107047, {Link} <\/p>\n\n\n\n

26. Crispino M, et al.<\/em>, Role of the Serotonin Receptor 7 in Brain Plasticity: From Development to Disease. <\/em>Int J Mol Sci, 2020<\/strong>. 21(2), {Link} <\/p>\n\n\n\n

27. Lee J, et al.<\/em>, Modulation of Serotonin Receptors in Neurodevelopmental Disorders: Focus on 5-HT7 Receptor. <\/em>Molecules, 2021<\/strong>. 26(11), {Link} <\/p>\n\n\n\n

28. Okubo R, et al.<\/em>, Current Limitations and Candidate Potential of 5-HT7 Receptor Antagonism in Psychiatric Pharmacotherapy. <\/em>Front Psychiatry, 2021<\/strong>. 12, 623684, {Link} <\/p>\n\n\n\n

29. Olusakin J, et al.<\/em>, Implication of 5-HT7 receptor in prefrontal circuit assembly and detrimental emotional effects of SSRIs during development. <\/em>Neuropsychopharmacology, 2020<\/strong>. 45(13), 2267-2277, {Link} <\/p>\n\n\n\n

30. Bijata M, et al.<\/em>, Activation of the 5-HT7 receptor and MMP-9 signaling module in the hippocampal CA1 region is necessary for the development of depressive-like behavior. <\/em>Cell Rep, 2022<\/strong>. 38(11), 110532, {Link} <\/p>\n\n\n\n

31. Watts S W<\/strong>, et al.<\/em><\/strong>, 5-HT is a potent relaxant in rat superior mesenteric veins<\/strong>. <\/em><\/strong>Pharmacol Res Perspect, 2015. 3(1), e00103, <\/strong>{Link} <\/strong><\/p>\n\n\n\n

32. Seitz B M<\/strong>, et al.<\/em><\/strong>, Reduction in Hindquarter Vascular Resistance Supports 5-HT(7) Receptor Mediated Hypotension<\/strong>. <\/em><\/strong>Front Physiol, 2021. 12, 679809, <\/strong>{Link} <\/strong><\/p>\n\n\n\n

33. Davis R P<\/strong>, et al.<\/em><\/strong>, One-month serotonin infusion results in a prolonged fall in blood pressure in the deoxycorticosterone acetate (DOCA) salt hypertensive rat<\/strong>. <\/em><\/strong>ACS Chem Neurosci, 2013. 4(1), 141-148, <\/strong>{Link} <\/strong><\/p>\n\n\n\n

34. Seitz B M<\/strong>, et al.<\/em><\/strong>, 5-HT causes splanchnic venodilation<\/strong>. <\/em><\/strong>Am J Physiol Heart Circ Physiol, 2017. 313(3), H676-H686, <\/strong>{Link} <\/strong><\/p>\n\n\n\n

35. Seitz B M<\/strong>, et al.<\/em><\/strong>, 5-HT does not lower blood pressure in the 5-HT(7) knockout rat<\/strong>. <\/em><\/strong>Physiol Genomics, 2019. 51(7), 302-310, <\/strong>{Link} <\/strong><\/p>\n\n\n\n

36. Kim J J and W I Khan, 5-HT7 receptor signaling: improved therapeutic strategy in gut disorders. <\/em>Front Behav Neurosci, 2014<\/strong>. 8, 396, {Link} <\/p>\n\n\n\n

37. Zou B C, et al.<\/em>, Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome. <\/em>Chin Med J (Engl), 2007<\/strong>. 120(23), 2069-2074, {Link} <\/p>\n\n\n\n

38. Guseva D, et al.<\/em>, Serotonin 5-HT7 receptor is critically involved in acute and chronic inflammation of the gastrointestinal tract. <\/em>Inflamm Bowel Dis, 2014<\/strong>. 20(9), 1516-1529, {Link} <\/p>\n\n\n\n

39. Kim J J, et al.<\/em>, Targeted inhibition of serotonin type 7 (5-HT7) receptor function modulates immune responses and reduces the severity of intestinal inflammation. <\/em>J Immunol, 2013<\/strong>. 190(9), 4795-4804, {Link} <\/p>\n\n\n\n

40. Arreola R, et al.<\/em>, Immunomodulatory effects mediated by serotonin. <\/em>J Immunol Res, 2015<\/strong>. 2015, 354957, {Link} <\/p>\n\n\n\n

41. Ito M, et al.<\/em>, Brain regulatory T cells suppress astrogliosis and potentiate neurological recovery. <\/em>Nature, 2019<\/strong>. 565(7738), 246-250, {Link} <\/p>\n\n\n\n

42. Leon-Ponte M, et al.<\/em>, Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. <\/em>Blood, 2007<\/strong>. 109(8), 3139-3146, {Link} <\/p>\n\n\n\n

43. Layunta E, et al.<\/em>, Crosstalk Between Intestinal Serotonergic System and Pattern Recognition Receptors on the Microbiota-Gut-Brain Axis. <\/em>Front Endocrinol (Lausanne), 2021<\/strong>. 12, 748254, {Link} <\/p>\n\n\n\n

44. Del Colle A<\/strong>, et al.<\/em><\/strong>, Novel aspects of enteric serotonergic signaling in health and brain-gut disease<\/strong>. <\/em><\/strong>Am J Physiol Gastrointest Liver Physiol, 2020. 318(1), G130-G143, <\/strong>{Link} <\/strong><\/p>\n\n\n\n

45. Gershon M D and K G Margolis, The gut, its microbiome, and the brain: connections and communications<\/strong>. <\/em><\/strong>J Clin Invest, 2021. 131(18), <\/strong>{Link} <\/strong><\/p>\n\n\n\n

46. Hoffman J M and K G Margolis, Building community in the gut: a role for mucosal serotonin<\/strong>. <\/em><\/strong>Nat Rev Gastroenterol Hepatol, 2020. 17(1), 6-8, <\/strong>{Link} <\/strong><\/p>\n\n\n\n

47. Jenkins T A, et al.<\/em>, Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis. <\/em>Nutrients, 2016<\/strong>. 8(1), {Link} <\/p>\n\n\n\n

48. Israelyan N<\/strong>, et al.<\/em><\/strong>, Effects of Serotonin and Slow-Release 5-Hydroxytryptophan on Gastrointestinal Motility in a Mouse Model of Depression<\/strong>. <\/em><\/strong>Gastroenterology, 2019<\/strong>. 157(2), 507-521 e504, {Link} <\/p>\n\n\n\n

49. Deraredj Nadim W<\/strong>, et al.<\/em><\/strong>, Physical interaction between neurofibromin and serotonin 5-HT6 receptor promotes receptor constitutive activity<\/strong>. <\/em><\/strong>Proc Natl Acad Sci U S A, 2016. 113(43), 12310-12315, <\/strong>{Link} <\/strong><\/p>\n\n\n\n

50. Morisset S<\/strong>, et al.<\/em><\/strong>, High constitutive activity of native H3 receptors regulates histamine neurons in brain<\/strong>. <\/em><\/strong>Nature, 2000. 408(6814), 860-864, <\/strong>{Link} <\/strong><\/p>\n\n\n\n

51. Alagille D<\/strong>, et al.<\/em><\/strong>, Evaluation of [F-18]MNI-709 and [F-18]MNI-711 as potential 5HT(7) PET imaging agents. <\/strong>. <\/em><\/strong>J. Labelled Compd. Radiopharm 2014. S309, <\/strong><\/p>\n\n\n\n

52. Badarau E<\/strong>, et al.<\/em><\/strong>, SAR studies on new bis-aryls 5-HT7 ligands: Synthesis and molecular modeling<\/strong>. <\/em><\/strong>Bioorg Med Chem, 2010. 18(5), 1958-1967, <\/strong>{Link} <\/strong><\/p>\n\n\n\n

53. Badarau E<\/strong>, et al.<\/em><\/strong>, New insights into homopiperazine-based 5-HT1A\/5-HT7R ligands: synthesis and biological evaluation<\/strong>. <\/em><\/strong>J Enzyme Inhib Med Chem, 2010. 25(3), 301-305, <\/strong>{Link} <\/strong><\/p>\n\n\n\n

54. Badarau E<\/strong>, et al.<\/em><\/strong>, Benzimidazolone-based serotonin 5-HT1A or 5-HT7R ligands: synthesis and biological evaluation<\/strong>. <\/em><\/strong>Bioorg Med Chem Lett, 2009. 19(6), 1600-1603, <\/strong>{Link} <\/strong><\/p>\n\n\n\n

55. Reverchon F<\/strong>, et al.<\/em><\/strong>, T Lymphocyte Serotonin 5-HT(7) Receptor Is Dysregulated in Natalizumab-Treated Multiple Sclerosis Patients<\/strong>. <\/em><\/strong>Biomedicines, 2022. 10(10), <\/strong>{Link} <\/strong><\/p>\n\n\n\n

56. Morisset-Lopez S<\/strong>, et al.<\/em><\/strong>, Applications of biased ligands of the serotonin 5-ht7 receptor for the treatment of pain, multiple sclerosis and the control of thermoregulation<\/strong>. <\/em><\/strong>Patent EUROPE n\u00b0 21315045.1, 2021, <\/strong><\/p>\n\n\n\n

57. Matthes S<\/strong>, et al.<\/em><\/strong>, Tryptophan hydroxylase as novel target for the treatment of depressive disorders<\/strong>. <\/em><\/strong>Pharmacology, 2010. 85(2), 95-109, <\/strong>{Link} <\/strong><\/p>\n\n\n\n

58. Matthes S<\/strong>, et al.<\/em><\/strong>, Targeted Manipulation of Brain Serotonin: RNAi-Mediated Knockdown of Tryptophan Hydroxylase 2 in Rats<\/strong>. <\/em><\/strong>ACS Chem Neurosci, 2019. 10(7), 3207-3217, <\/strong>{Link} <\/strong><\/p>\n\n\n\n

59. Bader M, Serotonylation: Serotonin Signaling and Epigenetics<\/strong>. <\/em><\/strong>Front Mol Neurosci, 2019. 12, 288, <\/strong>{Link} <\/strong><\/p>\n\n\n\n

60. Specker E<\/strong>, et al.<\/em><\/strong>, Structure-Based Design of Xanthine-Imidazopyridines and -Imidazothiazoles as Highly Potent and In Vivo Efficacious Tryptophan Hydroxylase Inhibitors<\/strong>. <\/em><\/strong>J Med Chem, 2023. 66(21), 14866-14896, <\/strong>{Link} <\/strong><\/p>\n\n\n\n

61. Hogendorf A S, et al.<\/em>, Low-basicity 5-HT(7) Receptor Agonists Synthesized Using the van Leusen Multicomponent Protocol. <\/em>Sci Rep, 2017<\/strong>. 7(1), 1444, {Link} <\/p>\n\n\n\n

62. Latacz G, et al.<\/em>, Search for a 5-CT alternative. In vitro and in vivo evaluation of novel pharmacological tools: 3-(1-alkyl-1H-imidazol-5-yl)-1H-indole-5-carboxamides, low-basicity 5-HT(7) receptor agonists. <\/em>Medchemcomm, 2018<\/strong>. 9(11), 1882-1890, {Link} <\/p>\n\n\n\n

63. Hogendorf A S, et al.<\/em>, 2-Aminoimidazole-based antagonists of the 5-HT(6) receptor – A new concept in aminergic GPCR<\/span> ligand design. <\/em>Eur J Med Chem, 2019<\/strong>. 179, 1-15, {Link} <\/p>\n\n\n\n

64. Kalinowska-Tluscik J, et al.<\/em>, The effect of the intramolecular C-Hcdots, three dots, centeredO interactions on the conformational preferences of bis-arylsulfones – 5-HT(6) receptor antagonists and beyond. <\/em>RSC Adv, 2018<\/strong>. 8(33), 18672-18681, {Link} <\/p>\n\n\n\n

65. Staron J, et al.<\/em>, Pyrano[2,3,4-cd]indole as a Scaffold for Selective Nonbasic 5-HT(6)R Ligands. <\/em>ACS Med Chem Lett, 2017<\/strong>. 8(4), 390-394, {Link} <\/p>\n